Back in June 2012, we recommended that you pick up shares of Big Pharma player Abbott Laboratories Inc. (NYSE: ABT). The reason: Abbott was planning to split in two at the end of the year, meaning folks who took our advice would end up with stakes in two companies for the price of one.
There was more than bargain-basement thinking at work here.
You see, these corporate breakups - known as spin-offs - have a habit of turning into market-beating profit plays. And the newly minted spin-off firms often end up as takeover fodder - also at big profits.
This is premium content for Private Briefing subscribers only.